Repository logo
 

Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Parthymos, Ioannis 
Kostapanos, Michael S  ORCID logo  https://orcid.org/0000-0002-7513-5319
Liamis, George 

Abstract

Hypertriglyceridemia has been identified as a risk factor for cardiovascular disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.

Description

Keywords

apolipoprotein C-III, fibroblast growth 21 factor, lipoprotein lipase, triglycerides, volanesorsen, ω-3 fatty acids

Journal Title

J Cardiovasc Dev Dis

Conference Name

Journal ISSN

2308-3425
2308-3425

Volume Title

9

Publisher

MDPI AG